Immune-Related Adverse Events Associated with Atezolizumab: Insights from Real-World Pharmacovigilance Data
Antibodies · 15.07.2024 · 13 (3) · 56
DOI: 10.3390/antib13030056 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antibodies, online erschienen am 15.07.2024. Verfasst von Connor Frey und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of British Columbia, 317-2194 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
The advancement of immuno-oncology has brought about a significant shift in cancer treatment methods, with antibody-based immune checkpoint inhibitors like atezolizumab leading the way in this regard. However, the use of this checkpoint blockade can result in immune-related adverse events due to increased T-cell activity. The full spectrum of these events is not yet completely understood. In this study, the United States FDA Adverse Event Reporting System (FAERS) was utilized to investigate immune-related adverse events linked with the use of atezolizumab. The study identified forty-nine immune-related adverse events that affected multiple organ systems, including cardiovascular, respiratory, hematologic, hepatic, renal, gastrointestinal, neurologic, musculoskeletal, dermatologic, endocrine, and systemic disorders. The strongest signals for relative risk occurred for immune-mediated encephalitis (RR = 93.443), autoimmune myocarditis (RR = 56.641), immune-mediated hepatitis (RR = 49.062), immune-mediated nephritis (RR = 40.947), and autoimmune arthritis (RR = 39.382). Despite the morbidity associated with these adverse events, emerging evidence suggests potential associations with improved survival outcomes. Overall, this report sheds light on the widespread immune-related adverse events that cause significant morbidity and mortality in patients with cancer being treated with atezolizumab and brings attention to them for the clinicians treating these patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, University of British Columbia, 317-2194 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada.
- Department of Ophthalmology and Visual Sciences, University of British Columbia, 2550 Willow Street, Vancouver, BC V5Z 3N9, Canada.
ORCID-Profile: Connor Frey
Zitieren
APA
Frey, C., & Etminan, M. (2024). Immune-Related Adverse Events Associated with Atezolizumab: Insights from Real-World Pharmacovigilance Data. Antibodies, 13(3), 56. https://doi.org/10.3390/antib13030056
Vancouver
Frey C, Etminan M. Immune-Related Adverse Events Associated with Atezolizumab: Insights from Real-World Pharmacovigilance Data. Antibodies. 2024;13(3):56. doi:10.3390/antib13030056
BibTeX
@article{Frey2024,
author = {Frey, Connor and Etminan, Mahyar},
title = {Immune-Related Adverse Events Associated with Atezolizumab: Insights from Real-World Pharmacovigilance Data},
journal = {Antibodies},
year = {2024},
volume = {13},
number = {3},
pages = {56},
doi = {10.3390/antib13030056}
}
EUVIMED